Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or... – Inactivation or attenuation; producing viral subunits
Patent
1994-08-15
1999-09-21
Scheiner, Laurie
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
Inactivation or attenuation; producing viral subunits
4351723, 4352351, 4241881, 4241991, 4242081, C12N 704, C12N 700, A61K 3912, A61K 3921
Patent
active
059553421
ABSTRACT:
The present invention is concerned with the ability to differentiate between infection by HIV and immunization with an immunogenic preparation. Accordingly, the present invention provides a non-infectious, non-replicating, HIV retrovirus-like particle containing a heterologous antigenic marker, comprising an assembly of (a) an env gene product; (b) a pol gene product; (c) a gag gene product; and, (d) at least one non-retroviral, non-mammalian antigenic marker. The antigenic marker may have between 5 and 100 amino acid residues. In one embodiment, the amino acid sequence contains a tobacco mosaic virus (TMV) epitope obtained from the coat protein. In another embodiment, the marker is inserted into the gag gene product at an antigenically-active insertion site. The presence of the antigenic marker enables recognition that antiserum containing anti-HIV antibodies has been generated by exposure to the non-infectious retrovirus-like particles, as opposed to wild-type HIV infection, by testing for antibodies specific to the antigenic marker.
REFERENCES:
Hunter, 1994, Sem. Virol. 5:71-83.
Karacostas et al., 1993, Virol. 193:661-671.
Rovinski et al., 1992, J. Virol. 66:4003-4012.
Perkins et al., 1991, J. Immunol. 146:2137-2144.
Sharma et al., 1993, Vaccine 11:1321-1326.
Haynes et al., 1991, AIDS Res. Human Retro. 7:17-27.
Zhao-Wen, 1980, Nuc. Acids Prot., Proc. Symp., 196-200.
Rovinski, B., et al, J. Virol. (1992), 66(7), 4003-2, Jul. 1992--"Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine".
Klein, M., AIDS Research and Human Retroviruses--vol. 10--Supplement 1, Aug. 1994--"Neutralizing activities of HIV-1 pseudovirions and T-B tandem epitopes".
Haynes, J.R. et al, The Vaccine Symposium, Toronto, Ontario, Canada, Oct. 1989. Molecular Immun. 28(3) 1991. pp. 231-234, "Strategy for Developing a Genetically-Engineered Whole-Virus Vaccine Against HIV".
Karacostas, V. Et al, Proceedings of the National Academy of Sciences of the USA, vol. 86, No. 22, Nov. 1, 1989, "Immunodeficiency Virus-Like Particles Produced by a Vaccinia Virus Expression Vector".
Yao-, Fei-Long et al, Biotechniques (1995), 18(3), pp. 372, 374--Mar. 1995, Gene assembly-aided mutagenesis (GAAM).
Wain-Hobson et al Cell, vol. 40, 9-17, Jan. 1985.
Alizon et al, 1984.
Min Jou et al, Cell, vol. 19, 683-696, Mar. 1980.
Myers et al, Human Retroviruses and Aids 1988.
Trifilleff et al, Molecular Immunology, vol. 28, No. 8, pp. 889-896, 1991.
Ulmer et al, 1993 Current Drugs Ltd. ISSN 0967-8298.
Westhof et al, Nature, vol. 311, Sep. 13, 1984, 123-1260.
Cao Shi-Xian
Klein Michel H.
Persson Roy
Rovinski Benjamin
Yao Fei-Long
Connaught Laboratories Limited
Parkin Jeffrey S.
Scheiner Laurie
LandOfFree
Non-infectious, replication-defective, self-assembling HIV-1 vir does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-infectious, replication-defective, self-assembling HIV-1 vir, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-infectious, replication-defective, self-assembling HIV-1 vir will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-79570